Program

Click here to download the detailed program.

Time Session Information - Wednesday April 24, 2019
12:00 - 13:00 Registration and Lunch
The Conceptual Challenges
13:00 - 13:20 The Challenge of PD as many Diseases - Clinical, Genetic, Pathologic, Environmental Variability
Anthony Lang, Toronto
Permission
Not
Granted
13:20 - 13:40 Challenges to Study Disease Modification in Non-Manifesting at Risk Subjects (gene carriers, “prodromal PD” using new MDS-Criteria)
Ron Postuma, Montreal
Permission
Not
Granted
13:40 - 14:00 Challenges in Neuropathology: Do “copathologies” represent modifiers of PD (Revision) or an invitation to reconsider PD nosology (Reconstruction)?
John Trojanowsi, Philadelphia

Download
14:00 – 14:20 The Challenge of Revision vs Reconstruction
Alberto Espay, Cincinnati

Download
14:20 – 14:50 Discussion
José Obeso, Madrid; Jon Stoessl, Vancouver
Not Applicable
14:50 – 15:15 Refreshment Break
EXPERIENCES IN OTHER DISEASES IN NEUROLOGY AND MEDICINE
15:15 – 15:35 Alzheimer's Disease - problems of retaining old constructs; examples of reasons for and successes in revising concepts of disease subtyping
George Perry, San Antonio

Download
15:35 – 15:55 Impact of Breast Cancer Molecular Subtypes on Clinical Decision-Making
Philippe Bedard, Toronto

Download
15:55 – 16:15 The Transformation of Cystic Fibrosis: Molecular therapies for a diverse range of genetic causes
Steven Rowe, Birmingham

Download
16:15 – 16:45 Discussion
Alberto Espay, Cincinnati; Francesca Morgante, London UK
Not Applicable
Time Session Information - Thursday April 25, 2019
7:00 - 8:00 Registration and Continental Breakfast
Disease Mechanisms
8:00 - 8:30 Transmission of Misfolded Proteins in Neurodegenerative Disorders: A Common Mechanism of Disease Progression
Virginia Lee, Philadelphia

Download
8:30 - 8:50 Mechanistic Insights into GBA1-Associated Parkinson’s Disease and Development of Targeted Therapies
Dmitri Krainc, Chicago

Download
8:50 - 9:10 A Genetic Basis for Synaptic-Endosomal Dysfunction in Parkinson’s Disease
Matt Farrer, Vancouver

Download
9:10 - 9:40 Discussion
Adriano Aguzzi, Zürich; Antonio Strafella, Toronto

Not
Applicable

9:40 - 10:10 Break
10:10 - 10:30 LRRK2 as a Therapeutic Target for Parkinson’s Disease – Revise or Reconstruct
Lorraine Kalia, Toronto

Download
10:30 - 10:50 Bioenergetic Determinants of Neuronal Vulnerability in Parkinson’s Disease
James Surmeier, Chicago
Permission
Not
Granted
10:50 - 11:10 Neuroinflammation and Role of the Microbiome in Parkinson Disease
David Standaert, Birmingham

Download
11:10 - 12:10 Discussion
Patrik Brundin, Grand Rapids; Andy Singleton, Bethesda
Not
Applicable
12:10 - 13:10 Lunch
TRANSPLANTATION & OTHER STRATEGIES directed primarily at augmenting dopamine function (Neurorescue/Neurorestoration-based treatments)
13:10 - 13:30 YES - Nigrostriatal dopamine will remain a primary target and reinnervation should be pursued
Roger Barker, Cambridge

Download
13:30 - 13:50 NO - Nigrostriatal dopamine will not remain a primary target and reinnervation should not be pursued.
Jeffrey Kordower, Chicago

Download
13:50 - 14:30 Rebuttal and Discussion
Andres Lozano, Alfonso Fasano, Toronto
Permission
Not
Granted
14:30 - 15:00 Break
BIG DATA, MACHINE LEARNING, NEW TECHNIQUES, VIRTUAL COHORTS
15:00 - 15:30 What do PD cohort studies tell us – one disease or many?
Caroline Williams-Gray, Cambridge

Download
15:30 - 16:00 Thermodynamically Inspired Biomarkers – Transferring Concepts from Physics and Ecology to Medicine
Rudi Balling, Luxembourg
Permission
Not
Granted
16:00 - 16:40 Discussion
Todd Sherer, New York; Ronan Fleming, Leiden

Not
Applicable

Time Session Information - Friday April 26, 2019
7:00 - 8:00 Registration and Continental Breakfast
Trials - Biomarkers, Trial designs, consortiums, etc. What can be pursued in the near future and how?
8:00 - 8:30 Fit-for-Purpose Applicationsn of Biomarkers in PD Drug Development
Jesse Cedarbaum, Boston
Permission
Not
Granted
8:30 - 9:00 Discussion
Ken Marek, New Haven
Not
Applicable
Trials - Trial designs including Lessons Learned
9:00 - 9:30 Lessons from Anti-Amyloid-β Immunotherapies in AD
Howard Chertkow, Toronto
Permission
Not
Granted
9:30 - 10:00 Role of Novel End-Points and Evaluations of Response
Michael Schwarzschild, Boston
Permission
Not
Granted
10:00 - 10:20 Break
10:20 - 10:50 Novel trial designs of “disease modifying therapy” in oncology (e.g., I-SPY2) and other diseases
Christopher Coffey, Iowa City
Permission
Not
Granted
10:50 - 11:20 Time for a New Framework for ‘Disease Modifying’ Clinical Trials in Parkinson’s Disease
Karl Kieburtz, Rochester
Permission
Not
Granted
11:20 - 11:50 Regulatory Modifications that Could Facilitate Development of a Neuroprotective Therapy for PD 
Warren Olanow, New York
Permission
Not
Granted
11:50 - 12:35 Discussion
Hubert Fernandez, Cleveland; Karl Kieburtz, Rochester; Warren Olanow, New York
Not
Applicable
12:35 - 12:50 Concluding Summary/Remarks
Anthony Lang, Toronto

Register
Returning Registrant

Date

April 24 – April 26, 2019

Rates

Non-physician Rate
(e.g. scientists, fellows, residents)
$395
Physician Rate $495

Location

Marriott Downtown at
CF Toronto Eaton Centre
525 Bay Street
Toronto, ON  M5G 2L2

More Information

Conference Services
conference@uhn.ca
416-597-3422 ext 3448